The BiosearchTech Blog

As we start to close in on a full year of the COVID-19 pandemic, molecular diagnostics labs are still facing supply chain challenges with their SARS-CoV-2 testing workflows, and these shortages are only expected to get worse as the Northern Hemisphere flu season gets underway. These challenges limit testing volume and delay the delivery of results that help individuals make decisions on quarantining, working, and traveling, and are essential for keeping communities safe as they navigate a return to normalcy. 

Following up with the panelists from our recent COVID-19 webinar, Part 3 of 3

In the previous two blog posts in this series, we shared insights from two of the panelists from our webinar, “How to establish COVID-19 diagnostics and keep up with demand,” covering testing scale up and issues related to sensitivity and accuracy. In this final post of the series, we ask our panelists to address questions about some of the most pressing issues of today and the near future.

Following up with the panelists from our recent COVID-19 webinar, Part 2 of 3

In the face of a rapidly evolving pandemic, testing labs are constantly having to adjust and adapt their existing workflows. In our recent webinar, “How to establish COVID-19 diagnostics and keep up with demand,” we assembled a panel of experts to share insights that can help testing labs find a path forward. In this continuation of our webinar follow-up conversation with panelists Eric Chow, PhD, and Kathleen Campau, PhD, we discuss questions from the webinar audience related to SARS-CoV-2 testing sensitivity and accuracy.

Following up with the panelists from our recent COVID-19 webinar, Part 1 of 3

The COVID-19 pandemic has presented testing labs around the world with a number of new challenges, and the community is still working out the best ways to meet the incredible testing need. To help labs continue to refine and improve their SARS-CoV-2 testing processes and workflows, LGC, Biosearch Technologies recently held an information-rich webinar, 'How to establish COVID-19 diagnostics and keep up with demand', with a panel of experts from both industry and academia. Here we follow-up with two of the panelists, Eric Chow, PhD, and Kathleen Campau, PhD, with additional questions from the audience on scaling up. 

As countries worldwide begin to ease lockdown restrictions during the pandemic and prepare to return to “normal” without a vaccine for COVID-19 or effective treatments in place, prudent testing measures need to be taken to suppress new infections. It is critical to test more people rapidly to identify who is infected, track them to avoid the disease from spreading and tracing with whom they have been in contact. Reverse transcription PCR (RT-PCR) testing method currently represents the majority of COVID-19 molecular diagnostics that helps identify individuals who are infected at the time of the test.

It may seem strange that a company known for transforming the global seed breeding industry is uniquely positioned to help COVID-19 testing labs overcome bottlenecks and rapidly scale-up testing. However, when you look at the problems testing labs are facing, it becomes clear that LGC, Biosearch Technologies has all the right tools for a rapid and robust pandemic response, even with the need to validate our Research Use Only (RUO) products for diagnostic testing. Today’s significantly altered conditions require new approaches and new solutions.

We’re not rejecting you, just your oligo

PCR is arguably one of the most enabling technologies of modern molecular biology, with a sensitivity that can detect incredibly small amounts of DNA. However, the sensitivity of the method is also one of the biggest challenges—when you can detect just a few molecules of DNA, inadvertent contamination can give you misleading data. Issues with contamination are especially critical in qPCR reactions for molecular diagnostics testing, such as for SARS-CoV-2 detection, where any contaminating template DNA, even if it’s just long fragments, can generate false positive results.

On March 25, 2020, the US Food and Drug Administration (FDA) held the first of a series of virtual town halls they will be holding to answer technical questions about developing, validating, and implementing tests to detect SARS-CoV-2. Elizabeth Hillebrenner and Timothy Stenzel, PhD, from the Center for Devices and Radiological Health (CDRH) provided an overview of the policies governing the development and deployment of SARS-CoV-2 tests as well as expanded guidance on the existing policies. One of the more interesting points they covered were the different scenarios where diagnostic test developers do not need to file for an emergency use authorisation (EUA), which the FDA put in place to expedite increased testing capabilities. We’ve summarised those scenarios here, although we recommend you use the links at the end of this post to see the source material from the FDA if you are considering any of these pathways.*

In the nearly three months since the first confirmed case of COVID-19, the outbreak has become a global crisis, with the World Health Organization (WHO) reporting 113,702 confirmed cases of COVID-19 as of March 10, 2020, with 80,924 of those cases in China and the remaining 32,778 cases spread across 109 countries¹.

*Since the original publication of this blog, LGC, Biosearch Technologies is now the only acceptable commercial supplier of CDC-qualified SARS-CoV-2 probe and primer kits labeled with BHQ dye. Learn more here.

As the COVID-19 pandemic challenges society with the largest public health crisis of modern times, testing is a crucial part of the response. In the United States (U.S.), getting tests into the community has been challenging, in part due to the need to obtain an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA); however, in recent weeks, the US government has been doing its best to partner with private industry where the FDA has been fast-tracking more EUAs in effort to making testing more widely available across the country.